Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginsenoside Rg3 plus TACE for liver cancer
ChiCTR-TRC-11001643Phase 4Completed
- Sponsor
- Fudan University
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ginsenoside Rg3 in liver cancer (2 arms), sponsored by Fudan University. Primary endpoint: overall survival. Started Oct 2011; status: completed.
02
Drugs
ginsenoside Rg3
03
Conditions
liver cancer
Beyond the preview
Go deeper on ChiCTR-TRC-11001643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001643.